Table 3. Propensity score estimation results in a logit model.
| Variables | Level | Coefficient | 95% CI for coefficient |
|---|---|---|---|
| Health facility (Ref: Public) | Private Not for Profit | -0.22 | (-1.07,0.63) |
| Sex (Ref: Male | Female | -0.28 | (-0.63,0.08) |
| Age group in years (Ref: 15–24 ) | 25–34 | -0.16 | (-0.62,0.31) |
| 35–44 | -0.29 | (-0.79,0.21) | |
| 45–54 | -0.45 | (-1.01,0.11) | |
| ≥55 | -0.09 | (-0.65,0.47) | |
| Anti-TB regimen (Ref: Category I) | Category II | -0.80 | (-1.74,0.14) |
| Type of TB patient (Ref: New BC-PTB) | Retreatment BC-PTB | 0.50 | (-0.20,1.21) |
| MTB load (Ref: ≤2+) | 3+ | 0.10 | (-0.30,0.50) |
| By GeneXpert | 0.66** | (0.24,1.07) | |
| Type of DOTS (Ref: Facility) | Community | 0.61 | (-0.53,1.75) |
| Treatment supporter (Ref: Yes) | No | -1.23** | (-2.01,-0.46) |
| Health facility site (Ref: Rural) | Urban | 0.67* | (0.05,1.29) |
| Level of TSR in the district (Ref: Low) | High | -1.02*** | (-1.51,-0.53) |
| Number of observations | 817 |
Note: 95% confidence intervals in brackets; Category I: 2RHZE/4RH and 2RHZE/6HE; Category II: 2RHZES/1RHZE/6RHE; DOTS: Directly Observed Therapy Short Course; MTB: Mycobacterium tuberculosis;
p < 0.05,
** p < 0.01,
*** p < 0.001 at 5% significance level;
Ref: Reference category; TSR: Treatment success rate.